Acticor Biotech
Created in 2013
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
410 3,908Activities
Technologies
Entity types
Location
29 Rue du Faubourg Saint-Jacques, 75014 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 37
SIREN
798483285Engaged corporates
10
9 4Added in Motherbase
5 years, 6 months ago
deeptech Value proposition
To treat the acute phase of ischemic stroke !
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.
Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.
However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.
This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
biotechnology, monoclonal antibody, drug development, thrombosis, stroke, TIA, Stroke, AVC, and healthcareOriginal language
To treat the acute phase of ischemic stroke !
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.
Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.
However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.
This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
To safely treat the acute phase of ischemic stroke
https://www.acticor-biotech.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Karista Startup accelerator & VC, Venture Capital and Private Equity Principals | Karista Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 21 Mar 2024 | | |
 Le Figaro Media, Newspaper Publishing | Le Figaro Media, Newspaper Publishing | Other 23 Jan 2024 | | |
 Anaxago Startup accelerator & VC, Venture Capital and Private Equity Principals | Anaxago Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 30 Jul 2023 | | |
 SATT Ouest Valorisation Research, Startup accelerator & VC, Research Services | SATT Ouest Valorisation Research, Startup accelerator & VC, Research Services | Other 16 Nov 2023 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Other 2 Jul 2023 | | |
 Agoranov Startup accelerator & VC, Technology, Information and Internet | Agoranov Startup accelerator & VC, Technology, Information and Internet | Not capitalistic Not partnership Event 1 Aug 2018 | | |
 Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Not capitalistic Not partnership Event 24 Jan 2020 | | |
 Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Not capitalistic Not partnership Event 10 Apr 2018 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 19 Feb 2024 | | |
 Fondation Adolphe de Rothschild NGO, Think Tank, Hospitals and Health Care | Fondation Adolphe de Rothschild NGO, Think Tank, Hospitals and Health Care | Not capitalistic Partnership Event 2 Dec 2020 24 Jan 2024 | | |